Hookipa Pharma (HOOK) News Today $2.02 -0.12 (-5.61%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period RBC Capital Downgrades HOOKIPA Pharma (HOOK)December 21 at 5:53 AM | msn.comRBC downgrades Hookipa, slashes price targetDecember 20 at 7:31 PM | msn.comEnanta Pharmaceuticals’ RSV Platform Advances: Buy Rating Affirmed on Promising Clinical DataDecember 10, 2024 | markets.businessinsider.comHOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shiftsNovember 27, 2024 | uk.investing.comHookipa Pharma price target lowered to $7 from $24 at JMP SecuritiesNovember 22, 2024 | finance.yahoo.comHookipa Pharma announces workforce reduction of 80%, pause of eseba-vec programNovember 21, 2024 | markets.businessinsider.comStrategic Shift and Partnership Potential Drive Buy Rating for HOOKIPA PharmaNovember 21, 2024 | markets.businessinsider.comCompanies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite RiskyNovember 17, 2024 | sg.finance.yahoo.comHookipa Pharma Reports Q3 Earnings Amid Strategic ChangesNovember 16, 2024 | markets.businessinsider.comHOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business UpdatesNovember 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)November 12, 2024 | markets.businessinsider.comHOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-BreakerNovember 12, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Hookipa Pharma (HOOK)November 12, 2024 | markets.businessinsider.comHOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-BreakerNovember 11, 2024 | globenewswire.comHOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024October 31, 2024 | globenewswire.comPositive Outlook on Hookipa Pharma Driven by Clinical Advancements and Active Scientific EngagementOctober 30, 2024 | markets.businessinsider.comHookipa Pharma doses first patients with eseba-vecOctober 30, 2024 | markets.businessinsider.comHOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck CancerOctober 30, 2024 | globenewswire.comHOOKIPA Pharma to Present Strong Preclinical HB-700 DatasetSeptember 24, 2024 | globenewswire.comHOOKIPA Pharma (NASDAQ:HOOK) Stock Quotes, Forecast and News SummarySeptember 11, 2024 | benzinga.comHOOKIPA Pharma Announces Board of Directors ChangesAugust 30, 2024 | globenewswire.comHOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comHookipa Pharma Inc (NASDAQ:HOOK) Short Interest UpdateHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) saw a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 26,800 shares, a drop of 71.3% from the July 31st total of 93,400 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 51,600 shares, the short-interest ratio is currently 0.5 days.August 27, 2024 | marketbeat.comHOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss ExpectationsAugust 11, 2024 | finance.yahoo.comBuy Rating and Price Target Increase for Hookipa Pharma Amid Clinical and Financial ProgressAugust 10, 2024 | markets.businessinsider.comHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 10, 2024 | finanznachrichten.deSquamous Cell Carcinoma Drugs Pipeline 2024 | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, ModernaAugust 10, 2024 | theglobeandmail.comHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 10, 2024 | finance.yahoo.comHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 8, 2024 | globenewswire.comBuy Rating Affirmed for Enanta Pharmaceuticals Amid Promising Clinical Developments and Robust Financial HealthAugust 6, 2024 | markets.businessinsider.comHookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 47.1% in JulyHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 95,300 shares, a growth of 47.1% from the June 30th total of 64,800 shares. Based on an average daily volume of 86,400 shares, the short-interest ratio is presently 1.1 days. Currently, 1.2% of the company's stock are sold short.July 29, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Forecasted to Earn Q2 2024 Earnings of ($1.48) Per ShareHookipa Pharma Inc (NASDAQ:HOOK - Free Report) - Leerink Partnrs upped their Q2 2024 EPS estimates for Hookipa Pharma in a research note issued on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($1.48) for the quarter, up froJuly 26, 2024 | marketbeat.comOptimistic Outlook for Hookipa Pharma’s Oncology Pipeline Prompts Buy RatingJuly 26, 2024 | markets.businessinsider.comHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 23, 2024 | finanznachrichten.deHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 22, 2024 | globenewswire.comShort Interest in Hookipa Pharma Inc (NASDAQ:HOOK) Decreases By 85.7%Hookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totalling 64,800 shares, a decline of 85.7% from the June 15th total of 453,000 shares. Based on an average trading volume of 88,300 shares, the short-interest ratio is currently 0.7 days. Approximately 0.8% of the shares of the company are sold short.July 11, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Sees Unusually-High Trading VolumeHookipa Pharma (NASDAQ:HOOK) Sees Strong Trading VolumeJuly 11, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Shares Scheduled to Reverse Split on Wednesday, July 10thHookipa Pharma Inc (NASDAQ:HOOK - Free Report) shares are going to reverse split before the market opens on Wednesday, July 10th. The 1-10 reverse split was announced on Wednesday, July 10th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 10th.July 8, 2024 | marketbeat.comHOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock SplitJuly 8, 2024 | globenewswire.comHookipa Pharma (NASDAQ:HOOK) Trading Down 2.4%Hookipa Pharma (NASDAQ:HOOK) Shares Down 2.4%July 6, 2024 | marketbeat.comHOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIVJuly 1, 2024 | globenewswire.comHC Wainwright Increases Hookipa Pharma (NASDAQ:HOOK) Price Target to $6.00HC Wainwright raised their target price on Hookipa Pharma from $5.00 to $6.00 and gave the company a "buy" rating in a report on Wednesday.June 5, 2024 | marketbeat.comHOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual MeetingJune 4, 2024 | globenewswire.comShort Interest in Hookipa Pharma Inc (NASDAQ:HOOK) Increases By 28.4%Hookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 826,200 shares, an increase of 28.4% from the April 30th total of 643,700 shares. Based on an average daily trading volume, of 854,300 shares, the short-interest ratio is currently 1.0 days. Currently, 1.1% of the shares of the stock are sold short.June 1, 2024 | marketbeat.comHOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual MeetingMay 30, 2024 | globenewswire.comBuy Rating Affirmed for Hookipa Pharma Amid Positive HB-200 Vaccine Trials and Robust Financial PositionMay 24, 2024 | markets.businessinsider.comHOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual MeetingMay 23, 2024 | globenewswire.comDeep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)May 21, 2024 | markets.businessinsider.comHookipa Pharma's (HOOK) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $5.00 target price on shares of Hookipa Pharma in a research report on Tuesday.May 21, 2024 | marketbeat.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16, 2024 | investorplace.com Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. HOOK Media Mentions By Week HOOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOOK News Sentiment▼-1.200.60▲Average Medical News Sentiment HOOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOOK Articles This Week▼31▲HOOK Articles Average Week Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunic News Today Skye Bioscience News Today Avalo Therapeutics News Today MediciNova News Today Context Therapeutics News Today Pyxis Oncology News Today Assembly Biosciences News Today Oramed Pharmaceuticals News Today Tonix Pharmaceuticals News Today Tiziana Life Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOOK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
